Pasar al contenido principal

NUEVOS ANTIVIRALES FRENTE A LA INFECCION POR EL VIRUS DEL NILO OCCIDENTAL (VNO) DIRIGIDOS A EVENTOS CLAVE EN LA REPLICACION VIRAL Y A FACTORES CELULARES

PID2022-137372OR-C22

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lipid-targeting antiviral strategies: Current state and future perspectives

  • Blázquez, Ana B.
  • Mingo-Casas, Patricia
  • Quesada, Ernesto
  • Priego, Eva María
  • Peréz-Pérez, María-Jesús
  • Martín-Acebes, M. A.
There is an urgent need for antiviral compounds effective against currently known and future viral threats. The development of host-targeting antivirals (HTAs) appears as an alternative strategy to fight viral infections minimizing the potential of resistant mutant development and potentially leading to the identification of broad-spectrum antiviral agents. Among the host factors explored for HTA strategy, lipids constitute an attractive target as many viruses, even genetically diverse, hijack specific lipids during their lifecycle. Multiple repurposing efforts have been performed to analyze the antiviral properties of lipid-targeting compounds. These studies include the analysis of the effects of cholesterol lowering drugs such as statins, cholesterol transport inhibitors, sphingolipid modulators, de novo lipogenesis inhibitors blocking fatty acid synthesis, compounds targeting glycerophospholipids or drugs interfering with lipid droplet metabolism. This review is focused on the current status of lipid-based or lipid-targeting antiviral strategies and their potential for the development of antiviral therapies, with special emphasis on those studies that have reached advanced stages of development such as efficacy studies in animal models or clinical trials. Whereas there is still a long way to go, multiple proof-of-concept studies and clinical evidence reinforce the therapeutic potential of these strategies warranting their further development into effective antiviral therapies., This work was supported by the Spanish Ministry of Science and Innovation AEI/10.13039/501100011033 under Grants PID2022-137372OR-C21 (to MAMA) and PID2022-137372OR-C22 (MJPP and EMP) and by the European Commission—NextGenerationEU through CSIC's Global Health Platform (PTI Salud Global). MJPP acknowledges the financial support of the CSIC Intramural project PIE202380E090. PMC was supported by an FPI fellowship from AEI/10.13039/501100011033 under Grant PRE2020-093374., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neutral sphingomyelinase 2 inhibition alters inflammatory gene expression signatures in the brain of mice infected with West Nile virus

  • Mingo-Casas, Patricia
  • Álvarez-Fernández, Hadrián
  • Blázquez, Ana-Belén
  • Esteban, Ana
  • Escribano-Romero, Estela
  • Jiménez de Oya, Nereida
  • Calvo-Pinilla, Eva
  • Peréz-Pérez, María-Jesús
  • Priego, Eva María
  • Martín-Acebes, Miguel A
West Nile virus (WNV) is a neurotropic flavivirus transmitted by the bites of infected mosquitoes. Severe forms of the disease include meningitis, encephalitis, acute flaccid paralysis, or even death, and survivors develop long-lasting sequelae. The damage induced by WNV does not only stem from viral multiplication but also arises from immune-related pathology linked to neuroinflammation. Certain sphingolipids are key players in WNV infection, neurodegenerative diseases and inflammatory disorders. Neutral sphingomyelinase 2 (nSMase2), catalyzes the conversion of sphingomyelin into ceramide and is essential for flavivirus multiplication. Thus, nSMase2 constitutes a promising therapeutic target for the development of dual-acting antiviral and anti-inflammatory therapies against WNV. The effect of an orally bioavailable and brain-penetrating prodrug of the potent nSMase2 inhibitor DPTIP (DPTIP-P1) was studied in WNV-infected mice. While no reduction in the viral load in the brain of infected animals was observed, WNV-induced expression of inflammatory markers was modulated, resulting in a reduced IL-1β expression in brain. Transcriptomic analyses revealed that treatment with the DPTIP prodrug also modulated the expression of various genes related to immune cell function without altering antiviral innate response. Among others, DPTIP-P1 reduced the expression of Lyz2, an inducible genetic marker associated with macrophage infiltration, and modified the expression of genes related to T cell activation such as Trbc1 and Ptnp22. These results identify nSMase2 inhibitors as a new type of immune modulators of WNV infection. The neuroprotective effects exerted by DPTIP-P1 could contribute to mitigate WNV-induced neuroinflammation and sequelae., This work was supported by the Spanish Ministry of Science and Innovation AEI/10.13039/501100011033 under Grants PID2019- 105117RR-C21 (to MAMA), PID2019-105117RR-C22 (to MJPP) and PID2020-119195RJ-I00 (to NJO); Spanish Ministry of Science and Innovation AEI/10.13039/501100011033 and FEDER, EU under grants PID2022-137372OR-C21 (to MAMA), PID2022-137372OR-C22 (MJPP and EMP), by Comunidad de Madrid under grant TEC-2024/BIO-66/ SALAINDEC-CM (to MAMA) and by the European Commission—NextGenerationEU through CSIC’s Global Health Platform (PTI Salud Global). PMC was supported by an FPI fellowship from AEI/ 10.13039/501100011033 under Grant PRE2020-093374. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Design, synthesis and evaluation of arylpurine-based sinefungin mimetics as zika virus methyltransferase inhibitors

  • Río, Natalia del
  • Arribas-Álvarez, Iván
  • Orduña, José-María
  • Sutto-Ortiz, Priscila
  • Neyts, Johan
  • Kaptein, Suzanne
  • Decroly, Etienne
  • Priego, Eva María
  • Peréz-Pérez, María-Jesús
Arylpurine derivatives were designed and synthesized to mimic sinefungin by targeting the SAM/SAH binding site of zika virus (ZIKV) methyltransferase (MTase). These compounds incorporate adenine or 6-methyl-7-deazapurine bases, while the ribose of sinefungin has been replaced by an aniline, linked to its amino acid chain via a CO or a CH2 unit. Compounds 18, 29 and 31 inhibited ZIKV 2'-O-MTase activity. Docking studies showed that compounds 18 and 29 interact with both the purine and amino acid binding sites, effectively mimicking sinefungin. In contrast, compound 31 has its amino acid chain positioned above the ribose binding site. Notably, compound 18 exhibited modest antiviral activity against ZIKV., This work was supported by grant PID2019-105117RR-C22 (to MJPP) funded by the Spanish Ministry of Science and Innovation AEI/10.13039/501100011033; grant PID2022-137372OR-C22 (to MJPP and EMP), funded by MCIN/AEI/10.13039/ 501100011033 and by “ERDF A way of making Europe”; grant numberPIE-202380E090(toMJPP)funded by AE CSIC and Grant Agreement No. 101137229 (to MJPP, ED and JN) funded by European Union's Horizon Europe research and innovation programme. We thank Lieve Naesens for kindly providing the SH-SY5Y cells. We thank Caroline Collard and Elke Maas for excellent technical assistance., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A tetrapodal tryptophan derivative with multiple exposed free carboxylic acids blocks host cell entry of omicron SARS-Cov-2 and respiratory syncytial virus

  • Martí-Marí, Olaia
  • Moreno-Simoni, Marta
  • Avilés-Alía, Ana Isabel
  • Rusu, Luciana
  • Forcada-Nadal, Alicia
  • Adhav, Anmol
  • López-Redondo, Marisa
  • Blázquez, Ana-Belén
  • Esteban, Ana
  • Jiménez de Oya, Nereida
  • Marina, Alberto
  • Rubio, Vicente
  • Llácer, José Luis
  • Gago, Federico
  • Martín-Acebes, M. A.
  • Peréz-Pérez, María-Jesús
  • Geller, Ron
  • San-Félix, Ana
Omicron sublineages of SARS-CoV-2 have accelerated the spread of the virus and facilitated immune escape. In this work, we demonstrate that compound 2, a potent HIV and enterovirus A71 (EV-A71) entry inhibitor previously discovered in our research group, also displays potent in vitro activity against different SARS-CoV-2 Omicron variants while showing no activity against the ancestral SARS-CoV-2 Wuhan strain. Moreover, its sodium salt (2-Na salt) exhibited in vivo antiviral activity in a murine model of Omicron BA.1. infection. Indeed, biophysical and cryo-EM studies revealed binding of 2-Na salt to the Omicron BA.1 spike (S) protein stabilizing a "closed" form in which ∼75% of the S particles have all RBDs down, unlike the usual "open" form with one RBD up. Such "closed" form decreases S avidity for the cellular receptor ACE2, thus inhibiting viral entry. Computer-assisted modeling studies strongly suggest that 2 can interact with the intersubunit cavity of the S trimer of the Omicron BA.1 subvariant, making use of the multivalency principle. In this context, compound 2 can be considered a pharmacological tool for studying and validating new antiviral strategies against Omicron variants. We also identified 2 as a potent inhibitor of RSV and the Ebola virus. The effectiveness of 2 against a diverse set of viruses of different families supports its use as a promising lead for the development of entry inhibitors against current and future viral infections, representing a meaningful advance in the field., Funding for this project was provided by grants SGL2021-03-009, SGL2103053, and SGL2021-03-052 from European Union Next Generation EU/PRTR through the CSIC Global Health Platform established by EU Council Regulation 2020/2094. The work was also supported by the Spanish Ministry of Science and Innovation AEI/10.13039/501100011033/FEDER, UE under projects PID2022-137372OR-C22 (M.-J.P.-P.), PID2022-136307OB-C21 (A.S.-F.), and PID2022-136307OB-C22 (F.G.) together with CSIC Intramural projects PIE202380E090 (M.-J.P.-P. and A.S.-F.) and PIE 202340E181 (M.A.M.-A.). V.R. and J.L.L. acknowledge the financial support provided by MICIN (grants PID2020-120322RB-C21 and PID2020-116880GB-I00, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Thioaryl imides, a novel familiy of potential SARS-COV-2 entry inhibitors identified through a high thoughput pseudotyped assay

  • Quesada, Ernesto
  • Lozano-Morcillo, Carla
  • Avilés-Alía, Ana Isabel
  • Fernández-Cabello, Víctor
  • Marlasca, Mónica
  • Camarasa Rius, María José
  • Peréz-Pérez, María-Jesús
  • Geller, Ron
Resumen del póster presentado a las IV Jornadas Científicas PTI+ Salud Global, celebradas del 28 al 29 de octubre de 2024 en el Auditorio Marie Curie – Parc Científic de la Unviersitat de València., Background. Although the WHO declared the end of the COVID-19 emergency in May 2023, the disease remains as a global public health threat and complete eradication of the causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains an elusive goal in the short to medium term1. Fortunately, this lethal pandemic has been controlled by the emergence of vaccines capable of inducing neutralizing antibodies that efficiently block infection. These vaccines were developed using revolutionary mRNA technical breakthroughs based on harmless fragments of the spike-shaped S protein (S-Protein). It must be noted that it is well established that SARS-CoV-2 infects cells through the interaction of the S-protein located on the surface of the virus with the angiotensin converting enzyme 2 (ACE2) cell receptors. In spite of these success, the main concerns regarding the contemporary clinical landscape of the disease are the emergence of new variants, particularly focused on mutations in the S-protein. Since the identification of the original Wuhan strain, there have been multiple variants of concern, like the Omicron variants, which evolved into five lineages, among them the XBB1.5, the currently most prevalent subvariant due to its enhanced immune evasion from protection provided by prior infections or vaccines. This emphasize the importance of identifying and developing new chemotherapeutics, including small molecules, to combat COVID infection by targeting the entry of the virus into the host cells as a still attractive strategy whether the antivirals under investigation are adapted to the prevalent S-protein variants2., Methods. High-throughput screening (HTS) assays based on pseudotyped vesicular stomatitis viruses expressing the currently prevailing S-protein of SARS-CoV-2 (VSV-S) can be considered as simple, reliable platforms for the rapid identification of novel compounds with potential as entry inhibitors (hits)3. We report herein the preliminary evaluation of a small chemical library on VSV-S pseudoparticles harboring the XBB.1.5 S protein in Vero E6 cells expressing the TMPRSS2 entry factor., Results. A library of 30 synthetic thioaryl imides provided by IQM were assayed by I2SysBio in this HTS platform. Evaluated compounds proved a noticeable ability to inhibit the virus attachment to the host cells, showing IC50 values in the range 0.2-7.0 µM whereas keeping selectivity indexes >10., Conclusions. The screening campaign allowed to identify a series of potential SARS-CoV-2 entry inhibitors (XBB.1.5). The most active molecule showed significant capability to selectively block the interaction between ACE2 and pseudotyped VSV-S (IC50=0.2 µM). Moreover, thioaryl imides are a largely unexplored family of chemicals. These promising results could encourage us to explore focused research aimed at providing a candidate with enhanced activity and improved properties for further evaluation., The Spanish Ministry of Science and Innovation AEI/10.13039/501100011033 (grants PID2022-136307OB- C21 and PID2022-137372OR-C22 (MICINN/AEI/10.13039/501100011033/ FEDER, UE) and NextGeneration (EU 2020/2094) CSIC Global Health Platform (PTI Salud Global) are acknowledged for financial support., No